Full-Time
Ophthalmic Surgical Trainer
Posted on 9/27/2025
RxSight
201-500 employees
Post-implantation adjustable intraocular lens system
No salary listed
Irvine, CA, USA
In Person
 Medical, Clinical & Veterinary (1) |
|---|
- Demonstrable ability to liaise with individuals of all levels, including surgeons, clinical staff and facility administrators.
- Significant surgical experience in ophthalmic surgical applications, with emphasis in Cataract Surgery.
- Proven and excellent communication skills, written and verbal.
- Ability to travel up to ~75% of the time.
- 4+ years Surgical experience in ophthalmic industry.
- Ability to legally operate a motor vehicle and travel without restriction in the applicable region of the world.
- Train Physicians and staff on RxSight Injector loading and delivery.
- Communicate with sites to identify key on-site personnel, set proper expectations to ensure full site readiness to accept RxSight technology prior to customer onboarding.
- Ensure staff supporting physicians are fully educated and trained on RxSight technology to full competence.
- Train per labeling and become certified specifically to LAL loading and delivery.
- Ensure continuous procedure and training adherence for trained staff and physicians by conducting periodic audits of the effectiveness of the Training program.
- Assist with customer complaint-handling and management, as applicable.
- Support new surgeon’s use of the injector system as required and ensure scrub techs and surgeons are certified for the use of the RxSight Injector System.
- Provide feedback for implementing and optimizing the use of LAL within the ASC.
- Monitor and update the Training Portal regularly to ensure accurate reflection of customer activity as well as training readiness of each customer site.
- Provide excellent Customer support for customers assigned within your geographical region as measured by periodic Customer Satisfaction Surveys.
- Assist with clinical data collection, analysis and presentation as needed.
- Clinical experience within the ophthalmic industry preferred.
RxSight develops medical devices for vision correction in cataract surgery. Its flagship product is the Light Adjustable Lens (LAL), an intraocular lens that can be adjusted after implantation using a Light Delivery Device (LDD) to achieve the best possible vision. How it works: after the LAL is implanted, doctors use controlled light exposure via the LDD to fine-tune the lens power post-operatively, allowing precise refractive outcomes before finalizing vision. How RxSight differs from competitors: instead of relying on fixed lenses, it offers an adjustable lens system that enables post-operative customization, paired with a dedicated delivery device and support for ophthalmologists and clinics to optimize patient results. Its goal is to improve quality of life for patients with cataracts and corneal astigmatism by delivering superior, individualized visual outcomes and expanding access to precise vision correction in the cataract market.
Company Size
201-500
Company Stage
IPO
Headquarters
Aliso Viejo, California
Founded
1997
Simplify's Take
What believers are saying
- 300,000 LAL implants since launch drive recurring LDD and accessory revenue.
- 80% of surveyed eye care professionals select LAL for themselves, boosting adoption.
- 91.2% accuracy within 0.50 D target refraction from ASCRS 2026 meta-analysis.
What critics are saying
- Q1 2026 revenue drops 18% to $30.9M as LDD placements fall to 20 units.
- Class action lawsuits over securities fraud from CFO Thunen's December 2025 exit erode investor trust.
- Patient glare, halos, and night vision issues post-adjustment spur corrective surgeries by Gulani.
What makes RxSight unique
- Light Adjustable Lens is the only FDA-approved IOL adjustable post-surgery via UV light.
- LAL corrects as low as 0.50 D astigmatism, unmatched by other US IOLs.
- LDD enables up to three 2-4 week postoperative adjustments for personalized vision.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Stock Options
Company Equity
Company News
RxSight highlights 300,000 Light Adjustable Lens implant milestone and strong scientific presence at ASCRS 2026. April 08, 2026 16:05 ET | Source: RxSight, Inc. WASHINGTON, April 08, 2026 (GLOBE NEWSWIRE) - RxSight, Inc. (NASDAQ: RXST) today announced, in advance of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, that over 300,000 Light Adjustable Lens(R)(LAL(R) implants have been performed since launch, marking a significant milestone in the company's pursuit to make customized vision correction widely available to patients. The RxSight(R) Light Adjustable Lens system is the first and only intraocular lens (IOL) technology that enables doctors to optimize a patient's vision after cataract surgery based on real-world visual feedback. "The 300,000 milestone is a testament to the skill and dedication of the doctors who have leveraged LAL technology to deliver best-in-class clinical outcomes for patients and strong financial performance for their practices," said Ron Kurtz, MD, President and Chief Executive Officer of RxSight. "Of note, the rapidly expanding body of clinical evidence supporting adjustable intraocular lens technology will also be featured at the ASCRS 2026 meeting in 35 scientific presentations." The 15 papers, 19 posters and 1 session included in these LAL presentations span a wide range of topics, from refractive accuracy to complex cases and evolving treatment strategies, highlighting both the versatility and impact of adjustability. Highlights include a presentation by Dr. Szabo (Newsome Eye, Tampa, FL), who reported binocular LAL outcomes in which 93.1% of patients achieved simultaneous 20/20 or better distance and J1 or better near, as well as a meta-analysis by Dr. Rabinovitch (Herzig Eye Institute, Ottawa, CA), demonstrating pooled accuracy with the LAL was 91.2% within 0.50 diopters of target refraction. Also at ASCRS 2026, RxSight is launching its "I Trust It with My Own Eyes" program, inspired by the growing number of ophthalmologists who have chosen the Light Adjustable Lens for their own eyes. The series shares the personal perspectives of these surgeons, offering a firsthand look at the technology that inspires the confidence they bring to their patients. Hear their stories at rxsight.com/event/ascrs-2026. RxSight continues to expand access to the Light Adjustable Lens through its growing network of trained surgeons and certified practices across the United States and select international markets. The company remains focused on redefining what's possible in cataract surgery by delivering personalized vision with exceptional precision. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight(R) Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens(R)(LAL(R)/LAL+(R), collectively the "LAL"), RxSight Light Delivery Device (LDD(TM) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding, among other things, RxSight's belief that IOL adjustability will define the future standard of care for cataract surgery and reflects a fundamental shift in expectations; growth trends for RxSight; and clinical evidence supporting adjustable IOL technology. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part I, Item 1A (Risk Factors) in the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC) on February 25, 2026, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law. Investor Relations Contact: Oliver Moravcevic VP, Investor Relations [email protected]
RxSight's fair value estimate has decreased to $10.17 from $10.39 following analyst updates responding to softer 2026 revenue guidance and the appointment of Mark Wilterding as CFO. Analysts maintain largely neutral ratings whilst adjusting price targets within a narrow range. Piper Sandler reduced its target to $10 from $11, citing 2026 revenue guidance of $120 million to $135 million falling below estimates. However, UBS raised its target to $9 from $8, maintaining a neutral rating. Morgan Stanley viewed the Q4 pre-announcement positively and expects Wilterding's CFO appointment to be well received given his Edwards experience. Revenue growth assumptions have increased to 3.63% from 3.42%, whilst the modelled net profit margin declined to 12.56% from 12.98%.
Midday stock roundup: Eledon rises 6.1% on preliminary results. Eledon Pharmaceuticals Inc. (Nasdaq: ELDN) rose 6.1% to $1.83 apiece with a $138 million market cap. Shares of the Irvine-based biotechnology company continue to grow since it reported positive preliminary results on Thursday from a few studies testing tegoprubart, Eledon's investigational anti-CD40L antibody. Eledon also revealed a $57.5 million underwritten public offering of common stock and pre-funded warrants that will fund operations into the second quarter of 2027. Aliso Viejo-based RxSight Inc. (Nasdaq: RXST) jumped 11% to $9.82 per share with a market cap of $405 million. The cataract lens maker posted preliminary fourth quarter results on Sunday; it expects Q4 revenue of $32.6 million, beating analysts' estimates. RxSight also appointed Mark Wilterding as its new chief financial officer, succeeding Shelley Thunen. Irvine-based loanDepot (NYSE: LDI), a non-bank provider of mortgages, jumped 27% to $3.10 per share for a market cap of $1.1 billion after President Trump told Fannie Mae and Freddie Mac to buy $200 billion of mortgage debt to improve home availability before the midterm elections in November. CG Oncology (Nasdaq: CGON) in Irvine increased 30% to $54.44 per share for a market cap of $4.4 billion after announcing an expedited timeline for Phase 3 PIVOT-006. Shares in Beta Bionics Inc. (Nasdaq: BBNX), a diabetes management innovations company in Irvine, fell 34% to $21.01 per share for a market cap of $925 million after the company reported preliminary fourth-quarter results. TECHNOLOGY Lantronix Inc. (Nasdaq: LTRX) increased 4.8% to $6.13 per share and a $241 million market cap. The Irvine-based firm, which provides Edge AI chips and Industrial IoT solutions, this week debuted a new drone reference platform, as well as the SmartEdge.ai Gateway and SmartSwitch.ai solutions that form an "integrated Edge AI surveillance and intelligent connectivity platform designed to enable real-time video analytics." The company also today announced that it is scheduled to attend the 28th Annual Needham Growth Conference in New York on Jan. 13. Huntington Beach-based Karman Holdings Inc. (NYSE: KRMN) jumped 11% to $101.39 and a $13.4 billion market cap. The company yesterday announced that it has agreed to buy Seemann Composites and Materials Sciences, which specialize in maritime defense technologies such as submarines, for a total consideration of $220 million. For more on Karman, see the Jan. 12 print issue of the Business Journal. Kura Sushi USA Inc. (Nasdaq: KRUS) rose 14% to $63.87 apiece with a $773 million market cap. Shares in the restaurant company are up after reporting first quarter results yesterday. Revenue increased 14% to $73.5 million, beating the average analysts' consensus. Shares of Irvine-based CG Oncology Inc. (Nasdaq: CGON) are up 3.7% to $41.87 with a market cap of $3.4 billion. The biopharmaceutical company said yesterday that CEO Arthur Kuan and COO Ambaw Bellete will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 15 in San Francisco. Irvine-based chipmaker Skyworks Solutions (Nasdaq: SWKS) is down 12% to $58.60 a share with a market cap of $8.8 billion. Shares for the company, which introduced new audio, mobile, automotive and gaming innovations at the tech show CES this week, are down nearly 40% from a year ago. At CES, the company unveiled SKY66424-11, which it says is the industry's first highly integrated Wi-SUN and LoRaWAN RF front-end module for smart home and smart city applications. Crude oil is down 1% to $56.54 a barrel a day after President Trump said that Venezuela will turn over between 30 million to 50 million barrels of oil to the U.S. Irvine-based chip company Mobix Labs (Nasdaq: MOBX) dropped 43% to 19 cents per share for a market cap of $11.5 million after announcing the pricing of its previously announced public offering of 30 million shares of its common stock for aggregate gross proceeds of approximately $6 million, prior to deducting the placement agent's fees and other offering expenses. The company had risen 33% yesterday after announcing a new facility. Lake Forest-based Staar Surgical Co. (Nasdaq: STAA) fell 12% to $21.09 per share for a market cap of $1 billion after Broadwood Partners thanked shareholders for rejecting a proposed sale of the company to Alcon Inc. "STAAR now has a renewed opportunity to truly shine," Broadwood said in a statement today. Irvine-based Mobix Labs Inc. (Nasdaq: MOBX) surged 33% to 36 cents per share with a market cap of $22 million. The chip company on Monday said it plans to consolidate West Coast operations under one roof at a new, larger military-approved facility designed to support increasing demand. Kura Sushi USA Inc. (Nasdaq: KRUS) rose 7% to $58.04 apiece with a $703 million market cap. Ahead of the restaurant company's fiscal first quarter report on Jan. 7, the general analyst consensus for Q1 revenue is a 13% increase to $73 million. However, analysts also expect a loss of 16 cents per share compared to a loss of eight cents per share a year ago. The Dow 30 increased 1.5% to 49,119.45 during midday trading. Crude oil rose 1.7% to $58.30 a barrel after the U.S. captured Venezuelan leader Nicolas Maduro over the weekend. Irvine-based Rivian Automotive Inc. (Nasdaq: RIVN) fell 1.7% to $19.38 per share with a market cap of $23 billion. The EV maker today announced production and delivery totals for the quarter and year ending Dec. 31, 2025. The company produced 10,974 vehicles and delivered 9,745 during the same period. For the full year, it produced 42,284 vehicles and delivered 42,247, an 18% decrease from a year ago. Staar Surgical Co. (Nasdaq: STAA) is up 2% to $23.57 per share with a market cap of $1.2 billion. The Motley Fool reported that Dallas-based Slotnik Capital and London-based Sand Grove Capital Management in the third quarter acquired 635,000 shares valued at $17 million and 829,123 shares totaling in $22.3 million in Staar, respectively. The shareholder meeting to approve whether the Alcon merger will take place or not is rescheduled to take place Jan. 6. Tilly's Inc. (Nasdaq: TLYS) is up 7% to $2 apiece with a $61 million market cap. Shares of the Irvine-based retailer have been moving higher over the past four weeks, up 27.2%, according to Zacks Equity Research, which noted that the brand "could be poised for a breakout." Mobix Labs (Nasdaq: MOBX) dropped 11% to 28 cents per share for a market cap of $17 million. Shares of the Irvine-based 5G chipmaker continued to slide after the company said it would delay its annual report, which is expected to reveal a wider net loss for fiscal 2025. 5G chip company Mobix Labs (Nasdaq: MOBX) in Irvine dropped 9.4% to 34 cents per share for a market cap of $21 million shortly after announcing it is delaying its annual report that will show a larger net loss for FY 2025. Space launch and services company Rocket Lab (Nasdaq: RKLB) jumped 3.5% to $72.41 per share for a market cap of $39 billion after Benzinga listed it among the Top 10 Large-Cap gainers last week. Rocket Lab is based in Long Beach and got its start in Huntington Beach. California First Leasing Corp. (OTCQX: CFNB) jumped 22% to $27.98 apiece with a $251 million market cap. With volume almost four times greater than the daily average, the Newport Beach-based investment firm hit a new 52-week high of $28 per share during midday trading. Veritone Inc. (Nasdaq: VERI), which has major operations in Irvine, was down 4.5% to $4.80 per share with a market cap of $439 million. Insider Monkey reported on Dec. 29 that while it acknowledged the AI company's potential as an investment, "we believe certain AI stocks offer greater upside potential and carry less downside risk." Crude oil climbed 2.4% to $58.09 a barrel as investors weigh peace talks in Ukraine, Bloomberg reported. Shimmick Corp. (Nasdaq: SHIM) climbed 14% to $3.24 and a $116 million market cap. Volume of the Irvine-based provider of infrastructure projects of 136,000 was more than five times the daily average. Infinity Bancorp (OTC: INFT) declined 10% to $12.57 and a $37 million market cap. Volume of the Santa Ana-based bank of 500 was about 45 times the daily average of 11 shares.
INVESTOR ALERT: Pomerantz law firm investigates claims on behalf of investors of RxSight, Inc. - RXST. News provided by. NEW YORK, Jan. 8, 2026 /PRNewswire/ - Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether RxSight and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On December 22, 2025, RxSight issued a press release announcing that its Chief Financial Officer, Shelley Thunen, would leave that role and remain with the Company until the sooner of the appointment of her successor or January 31, 2026. Financial services firm BTIG noted that Thunen's departure was surprising given early signs of operational improvement, followed a separate management reshuffle disclosed earlier in the month, and that the timing of multiple leadership transitions points to ongoing commercial challenges and could push a broader recovery further into 2026, despite some recent progress. On this news, RxSight's stock price fell $1.22 per share, or 9.98%, to close at $11.01 per share on December 23, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. SOURCE Pomerantz LLP
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against RxSight, Inc. ("RxSight" or the "Company") (NASDAQ:RXST) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired RxSight securities between November 7, 2024 and July 8, 2025, both dates inclusive (the "Class Period").